Urologic Cancer Research at Stanford

Our team of urologic cancer experts at Stanford is actively engaged in performing novel research and designing innovative clinical trials for all types of urologic cancers, including bladder, kidney and prostate cancers.

Research highlights include:

Bladder cancer

• Stem cell research aimed at developing new treatments
• Improved molecular analysis of tumors to guide treatment decisions
• Combination trials with targeted therapies, vaccine trials, and standard of care chemotherapies

Kidney cancer

• Active bi-monthly seminars that highlight work of Stanford researchers and facilitate collaboration
• Molecular profiling of kidney tumor tissue to develop biomarkers and better guide treatment
• Combination trials with targeted therapies and traditional chemotherapies
• New therapies that starve cancer cells of glucose
• Advanced imaging studies and minimally invasive diagnostic technologies

Prostate cancer

• Hedgehog signaling pathway discoveries that have led to development of novel therapies
• Molecular analysis of prostate tumors that may enhance treatment decisions
• Experimental anti-androgen hormone therapies that have recently been shown to increase patient survival
• Quality of life studies, including urinary incontinence
• Active surveillance studies: Evidence suggests that some low grade, early stage prostate cancers can be safely observed without treatment, so-called "active surveillance."